PubRank

Alex Sparreboom

Author PubWeight™ 189.53‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012 4.42
2 A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res 2012 2.95
3 Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 2002 2.84
4 Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. J Clin Oncol 2003 2.83
5 Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res 2011 2.52
6 Pharmacological effects of formulation vehicles : implications for cancer chemotherapy. Clin Pharmacokinet 2003 2.44
7 Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol 2002 2.44
8 Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005 2.36
9 Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 2005 2.23
10 Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009 2.20
11 Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002 2.16
12 Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007 2.15
13 Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol 2010 2.07
14 Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol 2002 1.99
15 Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 2008 1.95
16 Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol 2007 1.92
17 Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 2004 1.85
18 Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol 2005 1.81
19 Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? Oncologist 2007 1.78
20 A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin Cancer Res 2010 1.69
21 Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. J Clin Oncol 2011 1.60
22 Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. J Clin Oncol 2006 1.56
23 Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics. Am J Physiol Cell Physiol 2013 1.56
24 Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer 2005 1.54
25 Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol 2006 1.53
26 Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 2008 1.48
27 Interaction of imatinib with human organic ion carriers. Clin Cancer Res 2008 1.47
28 Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 2007 1.47
29 Interaction of Cisplatin with the human organic cation transporter 2. Clin Cancer Res 2008 1.46
30 Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 2003 1.42
31 Clinical pharmacokinetics of docetaxel : recent developments. Clin Pharmacokinet 2006 1.41
32 Medicinal cannabis in oncology practice: still a bridge too far? J Clin Oncol 2005 1.41
33 Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib. Cancer Biol Ther 2007 1.40
34 Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res 2006 1.40
35 Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 2006 1.38
36 Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 2004 1.36
37 Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009 1.35
38 Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther 2005 1.34
39 Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin Cancer Res 2008 1.34
40 Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 2005 1.33
41 Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther 2006 1.33
42 Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res 2004 1.31
43 Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol 2005 1.29
44 Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood 2011 1.25
45 Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2004 1.25
46 Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro 2005 1.24
47 Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res 2012 1.24
48 Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 2006 1.23
49 Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res 2002 1.22
50 ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res 2008 1.22
51 Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry. Anal Biochem 2004 1.21
52 Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel. Clin Cancer Res 2006 1.19
53 Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 2005 1.18
54 ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res 2004 1.16
55 Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res 2012 1.15
56 Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004 1.13
57 Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 2005 1.13
58 Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol Cancer Ther 2008 1.13
59 Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses. Clin Cancer Res 2003 1.12
60 Review of UCN-01 development: a lesson in the importance of clinical pharmacology. J Clin Pharmacol 2005 1.12
61 Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol 2002 1.10
62 Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 2004 1.10
63 Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004 1.09
64 Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. Anticancer Drugs 2007 1.09
65 Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci U S A 2013 1.08
66 Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther 2002 1.08
67 Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol 2004 1.08
68 Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol 2005 1.07
69 Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells. PLoS Comput Biol 2010 1.07
70 Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res 2010 1.06
71 Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin Pharmacol Ther 2005 1.05
72 Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. Cancer Res 2004 1.05
73 Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 2002 1.05
74 A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther 2005 1.04
75 Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist 2006 1.03
76 Chemotherapy dosing in overweight and obese patients with cancer. Nat Rev Clin Oncol 2013 1.02
77 Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase. Clin Cancer Res 2010 1.01
78 Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy. Ther Clin Risk Manag 2005 1.01
79 Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res 2005 1.01
80 Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets 2002 1.01
81 Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin Pharmacol Ther 2003 0.99
82 Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther 2006 0.99
83 Determination of 2-methoxyestradiol in human plasma, using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2005 0.99
84 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res 2013 0.97
85 Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 2004 0.97
86 Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resist Updat 2004 0.97
87 Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability. Clin Cancer Res 2004 0.96
88 Pharmacogenomic importance of ABCG2. Pharmacogenomics 2008 0.96
89 Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin Cancer Res 2004 0.95
90 Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms. Drug Metab Dispos 2008 0.95
91 Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005 0.94
92 Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor. J Chromatogr B Analyt Technol Biomed Life Sci 2003 0.92
93 Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer. Urology 2007 0.91
94 Pharmacogenetics of the organic anion transporting polypeptide 1A2. Pharmacogenomics 2009 0.90
95 Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol 2005 0.90
96 Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel. Anticancer Drugs 2002 0.90
97 Contribution of tumoral and host solute carriers to clinical drug response. Drug Resist Updat 2012 0.90
98 Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol. J Pharm Sci 2007 0.89
99 Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. Clin Cancer Res 2005 0.89
100 Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res 2007 0.89
101 Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors. J Clin Oncol 2005 0.88
102 Unexplored pharmacokinetic opportunities with microdosing in oncology. Clin Cancer Res 2007 0.88
103 A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer. Clin Cancer Res 2004 0.88
104 Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2. Ann Pharmacother 2010 0.88
105 Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors. Clin Cancer Res 2005 0.88
106 Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res 2005 0.88
107 Determination of paclitaxel in human plasma following the administration of Genaxol or Genetaxyl by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2006 0.87
108 Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen. Anticancer Res 2005 0.87
109 Cisplatin-induced downregulation of OCTN2 affects carnitine wasting. Clin Cancer Res 2010 0.87
110 Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol 2011 0.87
111 Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity. Mol Pharmacol 2013 0.87
112 Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics. Mol Cancer Ther 2013 0.86
113 CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin Cancer Res 2013 0.86
114 Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. Cancer Chemother Pharmacol 2005 0.85
115 Mechanism-based models for topotecan-induced neutropenia. Clin Pharmacol Ther 2004 0.85
116 Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy? J Clin Oncol 2005 0.85
117 Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clin Cancer Res 2006 0.84
118 Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches. Clin Pharmacol Ther 2003 0.84
119 Population pharmacokinetics of cisplatin in adult cancer patients. Cancer Chemother Pharmacol 2004 0.84
120 Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004 0.84
121 Indirect determination of the irinotecan metabolite 7-ethyl-10-O-glucuronyl-camptothecin in human samples. Anal Biochem 2004 0.84
122 O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives. Jpn J Cancer Res 2002 0.83
123 Pharmacogenetics of estrogen metabolism and transport in relation to cancer. Curr Drug Metab 2003 0.83
124 BSA-based dosing and alternative approaches. Clin Adv Hematol Oncol 2005 0.83
125 Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant. Cancer Immunol Immunother 2005 0.83
126 Pharmacogenetics of irinotecan disposition and toxicity: a review. Curr Clin Pharmacol 2010 0.82
127 Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. Anticancer Drugs 2008 0.82
128 Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). Clin Cancer Res 2013 0.82
129 Deoxycytidine kinase modulates the impact of the ABC transporter ABCG2 on clofarabine cytotoxicity. Cancer Res 2011 0.82
130 Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis. Anticancer Drugs 2003 0.82
131 Paclitaxel pharmacokinetics, threshold models, and dosing strategies. J Clin Oncol 2003 0.81
132 Impact of ABCB1 allelic variants on QTc interval prolongation. Clin Cancer Res 2010 0.81
133 Altered irinotecan metabolism in a patient receiving phenytoin. Anticancer Drugs 2002 0.81
134 Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity. Pharmacogenomics 2015 0.80
135 Determination of fraction unbound docetaxel using microequilibrium dialysis. Anal Biochem 2004 0.80
136 Inhibition of OCTN2-mediated transport of carnitine by etoposide. Mol Cancer Ther 2012 0.80
137 Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors. J Clin Oncol 2002 0.80
138 Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 2003 0.80
139 Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. Invest New Drugs 2006 0.80
140 Can "specific" OCT1 inhibitors be used to determine OCT1 transporter activity toward imatinib? Blood 2013 0.80
141 Appropriate chemotherapy dosing in obese patients with cancer. Nat Rev Clin Oncol 2013 0.80
142 Distribution of paclitaxel in plasma and cerebrospinal fluid. Anticancer Drugs 2003 0.79
143 Uptake carriers and oncology drug safety. Drug Metab Dispos 2013 0.79
144 Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. Oncologist 2007 0.79
145 Plasma protein binding of the investigational anticancer agent 2-methoxyestradiol. Anticancer Drugs 2006 0.79
146 Inhibition of imatinib transport by uremic toxins during renal failure. J Clin Oncol 2008 0.79
147 Liquid chromatographic assays for DE-310, a novel camptothecin analog, and two major enzymatic products in human matrices. J Chromatogr B Analyt Technol Biomed Life Sci 2004 0.78
148 Lifestyle habits as a contributor to anti-cancer treatment failure. Eur J Cancer 2008 0.78
149 Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice. J Exp Clin Cancer Res 2009 0.78
150 A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform. Clin Cancer Res 2013 0.78
151 Polymorphic transporters and platinum pharmacodynamics. Drug Metab Pharmacokinet 2012 0.78
152 Effect of valspodar on the pharmacokinetics of unbound paclitaxel. Invest New Drugs 2003 0.78
153 Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia. Oncologist 2010 0.77
154 Determination of topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2002 0.77
155 Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity. J Clin Oncol 2002 0.77
156 Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r). Cancer Biol Ther 2005 0.77
157 Long-term prospective population PK study in GIST patients--response. Clin Cancer Res 2013 0.77
158 Predicting vinorelbine disposition and toxicity: does BSA provide more than a "bad statistical association"? J Clin Oncol 2006 0.77
159 Limited cerebrospinal fluid penetration of docetaxel. Anticancer Drugs 2004 0.76
160 Identifying sources of interindividual pharmacokinetic variability with population modeling. Clin Cancer Res 2006 0.75
161 Can erlotinib ameliorate cisplatin-induced toxicities? J Clin Oncol 2013 0.75
162 PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics 2017 0.75
163 Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer. Clin Cancer Res 2004 0.75
164 Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2004 0.75
165 Clinical studies of camptothecin and derivatives. Alkaloids Chem Biol 2003 0.75
166 New directions in cancer research 2003: technological advances in biology, drug resistance, and molecular pharmacology. Drug Resist Updat 2003 0.75
167 Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan. Clin Cancer Res 2002 0.75
168 Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer. Clin Cancer Res 2003 0.75
169 Determination of SU5416, a novel angiogenesis inhibitor, in human plasma by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2004 0.75
170 The role of drug-metabolising enzymes in clinical responses to chemotherapy. Expert Opin Drug Metab Toxicol 2006 0.75